Beam Therapeutics to Unveil Updated BEAM-302 Trial Data at ERS Congress
Event summary
- Beam Therapeutics will present updated Phase 1/2 trial data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the ERS Congress on September 8, 2026.
- BEAM-302 is designed to correct the PiZ mutation in AATD, addressing both lung and liver disease.
- The presentation will be delivered by John Hurst, M.D., Ph.D., from University College London.
- Beam plans to initiate a pivotal cohort for BEAM-302 following the data presentation.
The big picture
Beam Therapeutics is advancing its lead genetic medicine program, BEAM-302, for Alpha-1 Antitrypsin Deficiency (AATD), a rare disease with significant unmet medical needs. The upcoming presentation at the ERS Congress marks a critical milestone in evaluating the therapy's potential to correct the underlying genetic mutation and provide a durable treatment option. With no current therapies addressing both lung and liver manifestations of AATD, BEAM-302 could position Beam as a key player in the genetic medicine space if clinical success is demonstrated.
What we're watching
- Clinical Efficacy
- How the updated data will demonstrate BEAM-302's potential to address both lung and liver disease in AATD patients.
- Regulatory Pathway
- Whether the Phase 1/2 results will support a smooth transition into pivotal trials for BEAM-302.
- Market Positioning
- The pace at which Beam can establish BEAM-302 as a leading therapy in the AATD space, given the lack of curative treatments currently available.
Related topics